TRCT
KLRS

Tower Research Capital (TRC)’s Kalaris Therapeutics KLRS Stock Holding History

Tower Research Capital (TRC)’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$802 Buy
+139
New +$1.23K ﹤0.01% 4775
2025
Q3 		– Sell
-2,153
Closed -$5.75K – 5756
2025
Q2 		$5.75K Buy
2,153
+719
+50% +$3.25K ﹤0.01% 4154
2025
Q1 		$11.5K Buy
1,434
+675
+89% +$6.61K ﹤0.01% 3532
2024
Q4 		$7.33K Buy
759
+658
+651% +$9.95K ﹤0.01% 4084
2024
Q3 		$1.88K Sell
101
-793
-89% -$13.9K ﹤0.01% 5087
2024
Q2 		$14.9K Buy
894
+452
+102% +$7.98K ﹤0.01% 3929
2024
Q1 		$7.68K Sell
442
-187
-30% -$3.05K ﹤0.01% 4167
2023
Q4 		$9.84K Buy
629
+351
+126% +$13.8K ﹤0.01% 4340
2023
Q3 		$13.7K Sell
278
-101
-27% -$6.88K ﹤0.01% 3755
2023
Q2 		$29.7K Buy
379
+288
+316% +$27.4K ﹤0.01% 3032
2023
Q1 		$8K Sell
91
-243
-73% -$31K ﹤0.01% 4682
2022
Q4 		$39K Buy
334
+205
+159% +$34.8K ﹤0.01% 2536
2022
Q3 		$23K Sell
129
-157
-55% -$24.5K ﹤0.01% 3832
2022
Q2 		$26K Buy
286
+49
+21% +$5.14K ﹤0.01% 3527
2022
Q1 		$37K Buy
237
+104
+78% +$20.7K ﹤0.01% 2972
2021
Q4 		$40K Buy
133
+24
+22% +$11.1K ﹤0.01% 2955
2021
Q3 		$63K Buy
109
+14
+15% +$6.48K ﹤0.01% 2774
2021
Q2 		$43K Buy
95
+23
+32% +$11.9K ﹤0.01% 3154
2021
Q1 		$38K Sell
72
-180
-71% -$151K ﹤0.01% 3362
2020
Q4 		$223K Buy
252
+93
+58% +$71.5K 0.01% 1622
2020
Q3 		$101K Buy
+159
New +$109K ﹤0.01% 3140

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Tower Research Capital (TRC)'s KLRS Position: Q1 2026 in Review

Tower Research Capital (TRC) opened a new position in Kalaris Therapeutics (KLRS) in Q1 2026: 139 shares worth $802. The stake represents ﹤0.01% of the portfolio and ranks #4775 among its holdings. This is a return to the name: Tower Research Capital (TRC) previously reported a position in KLRS as recently as Q2 2025.

Tower Research Capital (TRC) first reported a position in KLRS in Q3 2020 and has held it in 21 quarters since. The position peaked at $223K in Q4 2020. 58 funds tracked by Wall St. Rank hold KLRS as of Q1 2026.

  • Tower Research Capital (TRC) held 139 shares of Kalaris Therapeutics worth $802 as of Q1 2026.
  • Kalaris Therapeutics was a new Tower Research Capital (TRC) position in Q1 2026.
  • Kalaris Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #4775 holding.
  • Tower Research Capital (TRC) first reported a position in Kalaris Therapeutics in Q3 2020 and has held it in 21 quarters since.
  • Tower Research Capital (TRC)'s Kalaris Therapeutics position peaked at $223K in Q4 2020.
  • 58 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.